How BARDA Locked Up COVID-19 Vaccine Manufacturing Capacity For Operation Warp Speed

US agency avoided procurement delays with sole-source awards to two medical countermeasures venture partners worth nearly $900m.

Flexible Biomanufacturing Facility at Texas A&M
ciadm facilities dedicated to 'warp speed' vaccine manufacturing • Source: TAMUS

The government agency that develops medical countermeasures for the US stockpile says it had to move quickly to secure contract manufacturing plant capacity for COVID-19 vaccines before the private sector could “capture” it.

There was no time to give other contract manufacturers a chance to bid for the work, which the Health and...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Manufacturing

More from Compliance